These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37369789)

  • 1. Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.
    Sidik S
    Nature; 2023 Jul; 619(7968):19. PubMed ID: 37369789
    [No Abstract]   [Full Text] [Related]  

  • 2. Semaglutide (Ozempic) for weight loss.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):53-54. PubMed ID: 33830968
    [No Abstract]   [Full Text] [Related]  

  • 3. Ozempic keeps wowing: trial data show benefits for kidney disease.
    Fairbank R
    Nature; 2024 Jun; 630(8015):16-17. PubMed ID: 38789608
    [No Abstract]   [Full Text] [Related]  

  • 4. Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity.
    Villela R; Correa R
    J Investig Med; 2022 Jan; 70(1):3-4. PubMed ID: 34949728
    [No Abstract]   [Full Text] [Related]  

  • 5. Obesity drugs aren't always forever. What happens when you quit?
    Prillaman M
    Nature; 2024 Apr; 628(8008):488-490. PubMed ID: 38627513
    [No Abstract]   [Full Text] [Related]  

  • 6. Semaglutide for obesity: four STEPs forward, but more to come.
    Ryan DH
    Lancet Diabetes Endocrinol; 2021 May; 9(5):252-254. PubMed ID: 33864806
    [No Abstract]   [Full Text] [Related]  

  • 7. Semaglutide's Success Could Usher in a "New Dawn" for Obesity Treatment.
    Abbasi J
    JAMA; 2021 Jul; 326(2):121-123. PubMed ID: 34160581
    [No Abstract]   [Full Text] [Related]  

  • 8. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in Pharmacotherapy for Obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2021 Jul; 326(2):129-130. PubMed ID: 34160571
    [No Abstract]   [Full Text] [Related]  

  • 11. Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.
    Han SH; Safeek R; Ockerman K; Trieu N; Mars P; Klenke A; Furnas H; Sorice-Virk S
    Aesthet Surg J; 2023 Dec; 44(1):60-67. PubMed ID: 37402640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral semaglutide (Rybelsus) for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
    [No Abstract]   [Full Text] [Related]  

  • 13. Semaglutide as a promising antiobesity drug.
    Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
    Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 17. Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
    Verma RK; Sriramaneni R; Pandey M; Chaudhury H; Gorain B; Gupta G
    Panminerva Med; 2018 Dec; 60(4):224-225. PubMed ID: 29856185
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
    Hansen MB; Krogh Pedersen KL; Jia T
    Facial Plast Surg; 2023 Dec; 39(6):e2-e3. PubMed ID: 38604245
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.
    Aggarwal R; Vaduganathan M; Chiu N; Bhatt DL
    Prog Cardiovasc Dis; 2021; 68():97-98. PubMed ID: 34560122
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis.
    Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B
    J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.